Beyond Asthma : The Clinical Versatility of FeNO Testing
What is FeNO? Fractional exhaled Nitric Oxide (FeNO) is a non-invasive biomarker used to detect, monitor, and screen airway inflammation across a wide range of conditions — not just asthma.
Relevance to Asthma (Core Application)
While the infographic highlights FeNO’s versatility, its asthma-related utility remains central:
Monitoring Treatment Response — FeNO helps assess a patient’s adherence to inhaled corticosteroids (ICS) and guides ongoing steroid therapy decisions. Elevated FeNO in a patient on ICS may signal poor adherence or inadequate dosing.
Eosinophilic Inflammation — Elevated FeNO levels indicate eosinophilic airway inflammation, which directly guides anti-inflammatory treatment choices in asthma management.
Steroid-Responsive Phenotyping — In overlapping conditions like COPD, FeNO helps identify patients whose inflammatory profile resembles asthma and are likely to benefit from corticosteroids.
Broader Clinical Versatility
Condition
FeNO Characteristic
Clinical Value
Eosinophilic Inflammation
Elevated
Guides anti-inflammatory therapy
COPD & Chronic Cough
Variable
Identifies steroid-responsive phenotypes
Primary Ciliary Dyskinesia
Very low/Absent
Supports PCD diagnosis
Allergic/Atopic Conditions
Elevated
Detects eosinophilic inflammation in rhinitis & dermatitis
Occupational Screening
Variable
Screens for occupational asthma
Systemic Research
Variable
Links to hypertension & diabetes
Key Takeaway
FeNO is most established as an asthma management tool — particularly for guiding steroid therapy and confirming eosinophilic inflammation — but its utility is expanding into occupational health, rare diseases like PCD, and systemic disease research, making it a highly versatile non-invasive clinical tool.
Precision Pathways:Targeting the Asthma Inflammatory Cascade
The infographic maps how asthma’s inflammatory cascade unfolds from the airway epithelium downward, and where modern biologics intercept it.
Three main intervention zones are illustrated: Upstream Alarmin Blockade — The airway epithelium releases TSLP (thymic stromal lymphopoietin) in response to triggers. Tezepelumab blocks TSLP at this earliest point, suppressing both T2 and non-T2 inflammation before the cascade amplifies. Allergic & Eosinophilic Interruption — Allergens stimulate B cells to produce IgE, which drives allergic responses. Omalizumab binds free IgE to blunt this. Downstream, Th2 cells release IL-5, which recruits eosinophils. Mepolizumab targets IL-5, while Benralizumab targets the IL-5 receptor (IL-5R) directly, depleting tissue-damaging eosinophils more completely. Cytokine Receptor Inhibition — Th2 cells also release IL-4 and IL-13, which act on airway smooth muscle (causing remodeling) and goblet cells (causing mucus overproduction). Dupilumab blocks the shared IL-4/IL-13 receptor, addressing both pathological processes simultaneously. Biomarker-guided selection (blood eosinophils, IgE levels, FeNO) helps match the right biologic to the right patient. Clinical outcomes include a 40–70% reduction in severe attacks and emergency visits, corticosteroid elimination, and potential clinical remission.
Expanded Role of Biologics in Asthma
Why Biologics? Severe asthma affects roughly 5–10% of asthma patients but accounts for the majority of healthcare costs and morbidity. Traditional step-up therapy with inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), and oral corticosteroids (OCS) carries significant long-term toxicity and fails many patients. Biologics offer precision targeting of specific immunological pathways rather than broad immunosuppression.
The Five Approved Biologics in Detail 1. Omalizumab — Anti-IgE The first biologic approved for asthma (2003), it binds free circulating IgE, preventing it from binding to mast cells and basophils and triggering allergic responses. It is indicated for moderate-to-severe allergic asthma with elevated IgE and documented sensitization to a perennial allergen. It reduces exacerbations by ~25–50% and is particularly effective in atopic patients. 2. Mepolizumab — Anti-IL-5 Targets IL-5 directly, reducing eosinophil production and survival in the bone marrow and periphery. Indicated for severe eosinophilic asthma (blood eosinophils ≥150–300 cells/µL). Reduces exacerbations by ~50% and allows significant OCS dose reduction. Administered subcutaneously every 4 weeks. 3. Benralizumab — Anti-IL-5Rα Binds the IL-5 receptor alpha subunit on eosinophils and basophils, triggering antibody-dependent cell-mediated cytotoxicity (ADCC) — essentially causing near-complete eosinophil depletion rather than just blocking IL-5 signaling. This mechanism produces faster and more profound eosinophil reduction. Administered every 4 weeks for 3 doses, then every 8 weeks — a convenience advantage. 4. Dupilumab — Anti-IL-4Rα Blocks the shared IL-4/IL-13 receptor alpha chain, simultaneously inhibiting both IL-4 and IL-13 signaling. This dual blockade addresses multiple downstream effects: mucus hypersecretion, airway hyperresponsiveness, IgE production, and airway remodeling. It is approved for moderate-to-severe T2 asthma and also has indications for atopic dermatitis, chronic rhinosinusitis, and eosinophilic esophagitis — making it attractive for patients with overlapping atopic conditions. 5. Tezepelumab — Anti-TSLP The newest and most broadly applicable biologic. By blocking TSLP — an epithelial “danger signal” released in response to allergens, viruses, pollutants, and other triggers — it sits furthest upstream in the cascade. Crucially, it is effective in both T2-high and T2-low asthma phenotypes, unlike the other biologics which depend on T2 biomarkers. It has demonstrated efficacy even in patients with low eosinophils and low IgE, expanding the treatable population. Biomarker-Guided Patient Selection Matching the right biologic to the right patient is essential:
Clinical Outcomes Biologics have transformed severe asthma management in several key ways. Exacerbation rates fall by 40–70% across trials, with some patients achieving complete exacerbation freedom. OCS dependency — which causes adrenal suppression, osteoporosis, diabetes, and cardiovascular risk — can be eliminated in many patients. Perhaps most significantly, the concept of clinical remission (sustained symptom control, normal lung function, no exacerbations, off OCS) is now an achievable treatment goal rather than an aspiration, with remission rates of 20–40% reported in real-world biologic cohorts.
This infographic maps out how sarcoidosis can affect virtually every system in the body. Here’s a summary of the major topics covered:
Neurological :Cranial Nerve Palsy affects 5–15% of cases as part of neurosarcoidosis, with facial palsy (Cranial Nerve VII) being the most frequent finding.
Ocular:Ocular involvement occurs in 25–50% of cases. Anterior or posterior uveitis is the most common manifestation and can lead to vision loss if untreated.
Cardiac :Sarcoidosis can cause AV blocks or ventricular arrhythmias, and should be considered in young patients with unexplained heart block or syncope.
Hepatic & Splenic :Hepatosplenomegaly often presents asymptomatically, though elevated alkaline phosphatase may suggest a cholestatic pattern.
Renal: Beyond hypercalcemia-related issues, the kidneys can be affected by granulomatous interstitial nephritis and rarely proteinuria.
Metabolic:The hypercalcemia mechanism involves increased CYP27B1 activity in sarcoid macrophages, potentially causing renal stones and nephrocalcinosis.
Hematologic: Systemic sarcoidosis can present as anemia, leukopenia, or thrombocytopenia, often linked to hypersplenism.
Dermatologic: Erythema nodosum indicates a good prognosis, while lupus pernio (chronic skin lesions) signals a poorer long-term outlook.
Musculoskeletal: Bone cysts and arthritis include acute ankle arthritis, chronic arthropathy, and characteristic “lace-like” bone cysts in the phalanges.
Key Clinical Syndromes: Two notable syndromes are highlighted — Heerfordt Syndrome (uveitis, parotitis, facial palsy, and fever) and Löfgren Syndrome (erythema nodosum, bilateral hilar lymphadenopathy, and acute ankle arthritis).
